





Blood 142 (2023) 6761

# The 65th ASH Annual Meeting Abstracts

# ONLINE PUBLICATION ONLY

# 654.MGUS, AMYLOIDOSIS AND OTHER NON-MYELOMA PLASMA CELL DYSCRASIAS: CLINICAL AND EPIDEMIOLOGICAL

# Albumin: Globulin Reversal As a Screening Tool for Monoclonal Gammopathy (Targeted Screening) in Hospitalized Setting

Celine Raphael, BMBS<sup>1</sup>, Uday Yanamandra, MDDM<sup>2</sup>, Abhinav Kumar<sup>3</sup>, Narendra Kotwal<sup>3</sup>, Pankaj Malhotra, MD<sup>4</sup>, Velu Nair, MBBS,MD<sup>5</sup>

- <sup>1</sup> Internal Medicine and Hematology, Armed Forces Medical College, Pune, India
- <sup>2</sup>Internal Medicine and Hematology, Armed Forces Medical College, Pune, IND
- <sup>3</sup>Armed Forces Medical College, Pune, India
- <sup>4</sup>Department of Clinical Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
- <sup>5</sup>Apollo Hospitals Ahmedabad, Detrojrampura, IND

**Introduction:** There is an unmet need to discover novel targeted screening guidelines for Qmonoclonal gammopathy of undetermined clinical significance (MGUS) in the Indian scenario which can help in early detection and diagnosis. Liver function tests (LFTs) are routinely performed in hospital settings for a variety of indications, with many having albumin-globulin (A:G) ratio reversals. We have designed this study to gauge the prevalence of MGUS in individuals above the age of 50 years with A: G ratio reversal in hospitalized settings. The objectives of the study were to measure the incidence of A: G ratio reversal in total LFT samples run in the hospital for various indications and to determine whether targeted screening of unexplained A: G ratio reversal in hospitalized patients is a fruitful strategy.

### **Materials and Methods:**

This is a single-center, prospective observational study carried out from 01 May 2022 to 30 May 2023 at tertiary care center in Western India. All the LFTs of the admitted patients over the study period to the medical wards were included in the study. Patients with A:G reversal were subjected to detailed clinical examination and investigations to rule out non-myelomatous causes for the reversal of the ratio. Samples with unexplained A:G ratio reversal and unresolving A:G reversal despite of three months of observation were subjected to Serum Protein Electrophoresis (SPEP). Data was analysed using JMP ver. 16.0.0.

#### Results

A total of 5148 LFTs were screened during the study period, of which 300 (5.82%) had A:G reversal. The median age of the study population with A:G reversal was 59 years (IQR - 14.3) with a male preponderance (59%). Etiologically amongst patients with A:G reversal 54% had infection, 15% had inflammation, 13% suffer from Chronic Liver Disease and 9% have Chronic Kidney Disease. Only 9% of patients (n-27) had no evident secondary causes, and of these 11% (n-3) have an M-spike on SPEP. Of all patients with A:G reversal, 1.1% have evidence of MGUS, all being IgG Lambda variants and none having any features of smoldering or multiple myeloma based on IMWG guidelines.

# Conclusion:

**A** G reversal compounded with good clinical history and examination can be an effective tool for targeted screening of MGUS. A majority of A:G reversals in hospital settings are due to secondary causes, requiring deliberate effort for exclusion.

**Disclosures** No relevant conflicts of interest to declare.

https://doi.org/10.1182/blood-2023-191309